Xenoport (f/k/a XNPT)

[surf1944]

6:30AM Xenoport and GlaxoSmithKline (GSK) receive FDA approval for Horizant for postherpetic neuralgia (XNPT) 6.07 : GlaxoSmithKline (GSK) and XenoPort (XNPT) announced that the FDA has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults. The efficacy and safety of Horizant for the management of PHN was evaluated in a single 12-week principal efficacy trial, plus two supportive studies that all met their respective primary endpoints. The three clinical studies involved 574 adult patients from the US, Canada and Germany. In association with GSK's first commercial sale of the product after approval for PHN, XenoPort is entitled to a milestone payment of $10 million from GSK.